Breast cancer statistics, 2015: Convergence of incidence rates between black and white women

CA Cancer Journal for Clinicians

Volumn 66, Issue 1, 2016, Pages 31-42

  DeSantis, Carol E ^a   Fedewa, Stacey A ^a   Goding Sauer, Ann ^a   Kramer, Joan L ^b   Smith, Robert A ^a   Jemal, Ahmedin ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast neoplasms; epidemiology; screening and early detection

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AFRICAN AMERICAN; ALASKA NATIVE; AMERICAN INDIAN; ARTICLE; ASIAN; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER STATISTICS; CAUCASIAN; CAUSE SPECIFIC SURVIVAL; ETHNIC DIFFERENCE; FEMALE; GEOGRAPHIC DISTRIBUTION; HISPANIC; HUMAN; INVASIVE CARCINOMA; LUMINAL A BREAST CANCER; MAMMOGRAPHY; PACIFIC ISLANDER; PRIORITY JOURNAL; RACE DIFFERENCE; TRIPLE NEGATIVE BREAST CANCER; UNITED STATES; ADULT; AGE DISTRIBUTION; AGED; BREAST NEOPLASMS; CANCER REGISTRY; EARLY CANCER DIAGNOSIS; ETHNOLOGY; INCIDENCE; MASS SCREENING; MIDDLE AGED; MORTALITY; NON PROFIT ORGANIZATION; REGISTER; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; UTILIZATION; VERY ELDERLY;

ADULT; AFRICAN AMERICANS; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AMERICAN CANCER SOCIETY; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; REGISTRIES; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 84954372982     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21320     Document Type: Article

References (77)

1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER∗Stat Database: Incidence-SEER 18 Regs Research Data, Nov 2014 Sub (1992-2012) -Linked To County Attributes-Total US, 1969-2013 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2015.
2. Surveillance, Epidemiology, and End Results (SEER) Program. SEER∗Stat Database: Incidence-SEER 9 Regs Research Data with Delay-Adjustment, Malignant Only, Nov 2014 Sub (1975-2012) -Linked To County Attributes-Total US, 1969-2013 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2015.
3. Surveillance, Epidemiology, and End Results (SEER) Program: SEER∗Stat Database: Incidence-SEER 13 Regs Research Data with Delay-Adjustment, Malignant Only, Nov 2014 Sub (1992-2012) -Linked To County Attributes-Total US, 1969-2013 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2015.
4. Howlader N, Noone AM, Krapcho M, et al., SEER Cancer Statistics Review, 1975-2012, based on Nov 2014 SEER data submission. Bethesda, MD: National Cancer Institute; 2015.
5. Surveillance, Epidemiology and End Results (SEER) Program. SEER∗Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence-CiNA Analytic File, 1995-2012, Custom File With County, North American Association of Central Cancer Registries. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2015.
6. Copeland G, Lake A, Firth R, et al., Cancer in North America: 2008-2012. Volume One: Combined Cancer Incidence for the United States, Canada and North America. Springfield, IL: North American Association of Central Cancer Registries; 2015.
7. Copeland G, Lake A, Firth R, et al., Cancer in North America: 2008-2012. Volume Two: Registry-Specific Cancer Incidence for the United States, Canada and North America. Springfield, IL: North American Association of Central Cancer Registries; 2015.
8. Surveillance, Epidemiology, and End Results (SEER) Program. SEER∗Stat Database: Mortality-All COD, Aggregated With State, Total US (1969-2012) . Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2015. Underlying mortality data provided by the National Center for Health Statistics (cdc.gov/nchs).
9. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Data. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2012.
10. Siegel RL, Miller KD, Jemal A., Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29.
11. Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program, version 4.2.0.2, June 2015. Bethesda, MD: Statistical Research and Applications Branch, National Cancer Institute; 2015.
12. Statistical Research and Applications Branch, National Cancer Institute. DevCan: Probability of Developing or Dying of Cancer. DevCan software, version 6.7.3. Statistical Research and Applications Branch, National Cancer Institute, April 2015.
13. Danforth DN Jr., Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors [serial online]. Breast Cancer Res. 2013; 15: 208.
14. Silber JH, Rosenbaum PR, Clark AS, et al., Characteristics associated with differences in survival among black and white women with breast cancer. JAMA. 2013; 310: 389-397.
15. Ooi SL, Martinez ME, Li CI., Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat. 2011; 127: 729-738.
16. Curtis E, Quale C, Haggstrom D, Smith-Bindman R., Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer. 2008; 112: 171-180.
17. Chlebowski RT, Chen Z, Anderson GL, et al., Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005; 97: 439-448.
18. Martin JA, Hamilton BE, Osterman MJ, Curtin SC, Matthews TJ., Births: final data for 2013. Natl Vital Stat Rep. 2015; 64: 1-65.
19. Centers for Disease Control and Prevention (CDC). Breastfeeding among US Children Born 2002-2012: CDC National Immunization Surveys. cdc.gov/breastfeeding/data/nis-data/index.htm. Accessed August 4, 2015.
20. Blackwell DL, Lucas JW, Clarke TC., Summary health statistics for US adults: National Health Interview Survey, 2012. National Center for Health Statistics. Vital Health Stat 10. 2014;(260): 1-161.
21. Fedewa SA, Sauer AG, Siegel RL, Jemal A., Prevalence of major risk factors and use of screening tests for cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2015; 24: 637-652.
22. Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V., Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. Oncologist. 2014; 19: 805-813.
23. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70.
24. Perou CM, Sorlie T, Eisen MB, et al., Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
25. Tamimi RM, Colditz GA, Hazra A, et al., Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012; 131: 159-167.
26. Yang XR, Chang-Claude J, Goode EL, et al., Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011; 103: 250-263.
27. Barnard ME, Boeke CE, Tamimi RM., Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta. 2015; 1856: 73-85.
28. Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME., How many etiological subtypes of breast cancer: two, three, four, or more [serial online]? J Natl Cancer Inst. 2014; 106. pii: dju165.
29. Anderson WF, Rosenberg PS, Katki HA., Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer [serial online]. J Natl Cancer Inst. 2014; 106. pii: dju093.
30. Cheang MC, Martin M, Nielsen TO, et al., Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist. 2015; 20: 474-482.
31. Blows FM, Driver KE, Schmidt MK, et al., Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies [serial online]. PLoS Med. 2010; 7: e1000279.
32. Perou CM, Borresen-Dale AL., Systems biology and genomics of breast cancer [serial online]. Cold Spring Harb Perspect Biol. 2011; 3. pii: a003293.
33. Tao L, Gomez SL, Keegan TH, Kurian AW, Clarke CA., Breast cancer mortality in African-American and non-Hispanic white women by molecular subtype and stage at diagnosis: a population-based study. Cancer Epidemiol Biomarkers Prev. 2015; 24: 1039-1045.
34. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA., Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015; 313: 165-173.
35. Parise CA, Caggiano V., Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010 [serial online]. BMC Cancer. 2013; 13: 449.
36. Shi R, Taylor H, McLarty J, Liu L, Mills G, Burton G., Effects of payer status on breast cancer survival: a retrospective study [serial online]. BMC Cancer. 2015; 15: 211.
37. Sprague BL, Trentham-Dietz A, Gangnon RE, et al., Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer. 2011; 117: 1542-1551.
38. Halpern MT, Bian J, Ward EM, Schrag NM, Chen AY., Insurance status and stage of cancer at diagnosis among women with breast cancer. Cancer. 2007; 110: 403-411.
39. Harper S, Lynch J, Meersman SC, Breen N, Davis WW, Reichman MC., Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005). Cancer Epidemiol Biomarkers Prev. 2009; 18: 121-131.
40. Sullivan PD, Christine B, Connelly R, Barrett H., Analysis of trends in age-adjusted incidence rates for 10 major sites of cancer. Am J Public Health. 1972; 62: 1065-1071.
41. Devesa SS, Silverman DT, Young JL Jr, et al., Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst. 1987; 79: 701-770.
42. Toriola AT, Colditz GA., Trends in breast cancer incidence and mortality in the United States: implications for prevention. Breast Cancer Res Treat. 2013; 138: 665-673.
43. Rossouw JE, Anderson GL, Prentice RL, et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333.
44. Ravdin PM, Cronin KA, Howlader N, et al., The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356: 1670-1674.
45. Coombs NJ, Cronin KA, Taylor RJ, Freedman AN, Boyages J., The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control. 2010; 21: 83-90.
46. DeSantis C, Howlader N, Cronin KA, Jemal A., Breast cancer incidence rates in US women are no longer declining. Cancer Epidemiol Biomarkers Prev. 2011; 20: 733-739.
47. Breen N, Gentleman JF, Schiller JS., Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer. 2011; 117: 2209-2218.
48. Parkin DM., Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer. 2009; 45: 1649-1653.
49. Antoine C, Ameye L, Paesmans M, Rozenberg S., Update of the evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium. Maturitas. 2012; 72: 317-323.
50. Hemminki E, Kyyronen P, Pukkala E., Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2005. Maturitas. 2008; 61: 299-304.
51. Canfell K, Banks E, Moa AM, Beral V., Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust. 2008; 188: 641-644.
52. De P, Neutel CI, Olivotto I, Morrison H., Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst. 2010; 102: 1489-1495.
53. Zbuk K, Anand SS., Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health. 2012; 66: 1-7.
54. DeSantis C, Ma J, Bryan L, Jemal A., Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64: 52-62.
55. Bandera EV, Chandran U, Hong CC, et al., Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium. Breast Cancer Res Treat. 2015; 150: 655-666.
56. Berry DA, Cronin KA, Plevritis SK, et al., Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784-1792.
57. Munoz D, Near AM, van Ravesteyn NT, et al., Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality [serial online]. J Natl Cancer Inst. 2014; 106. pii: dju289.
58. Daly B, Olopade OI., A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin. 2015; 65: 221-238.
59. Goldman LE, Walker R, Miglioretti DL, Smith-Bindman R, Kerlikowske K,; National Cancer Institute Breast Cancer Surveillance Consortium. Accuracy of diagnostic mammography at facilities serving vulnerable women. Med Care. 2011; 49: 67-75.
60. Gorin SS, Heck JE, Cheng B, Smith SJ., Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med. 2006; 166: 2244-2252.
61. Allgood KL, Rauscher GH, Whitman S, Vasquez-Jones G, Shah AM., Validating self-reported mammography use in vulnerable communities: findings and recommendations. Cancer Epidemiol Biomarkers Prev. 2014; 23: 1649-1658.
62. Njai R, Siegel PZ, Miller JW, Liao Y., Misclassification of survey responses and black-white disparity in mammography use, Behavioral Risk Factor Surveillance System, 1995-2006 [serial online]. Prev Chronic Dis. 2011; 8. pii: A59.
63. Cronin KA, Miglioretti DL, Krapcho M, et al., Bias associated with self-report of prior screening mammography. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1699-1705.
64. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report: Cancer preventability estimates for diet, nutrition, body fatness, and physical activity. Washington, DC: American Institute for Cancer Research; 2015.
65. Jung S, Spiegelman D, Baglietto L, et al., Fruit and vegetable intake and risk of breast cancer by hormone receptor status. J Natl Cancer Inst. 2013; 105: 219-236.
66. Eliassen AH, Liao X, Rosner B, Tamimi RM, Tworoger SS, Hankinson SE., Plasma carotenoids and risk of breast cancer over 20 y of follow-up. Am J Clin Nutr. 2015; 101: 1197-1205.
67. Wang Y, Gapstur SM, Gaudet MM, Furtado JD, Campos H, McCullough ML., Plasma carotenoids and breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control. 2015; 26: 1233-1244.
68. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet. 2002; 360: 187-195.
69. Palmer JR, Viscidi E, Troester MA, et al., Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium [serial online]. J Natl Cancer Inst. 2014; 106. pii: dju237.
70. Millikan RC, Newman B, Tse CK, et al., Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008; 109: 123-139.
71. Ambrosone CB, Zirpoli G, Ruszczyk M, et al., Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women's Circle of Health Study. Cancer Causes Control. 2014; 25: 259-265.
72. Faupel-Badger JM, Arcaro KF, Balkam JJ, et al., Postpartum remodeling, lactation, and breast cancer risk: summary of a National Cancer Institute-sponsored workshop. J Natl Cancer Inst. 2013; 105: 166-174.
73. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE., Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat. 2013; 137: 579-587.
74. Gaudet MM, Press MF, Haile RW, et al., Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. 2011; 130: 587-597.
75. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI., Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer. 2008; 113: 1521-1526.
76. Oeffinger KC, Fontham ET, Etzioni R, et al., Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update from the American Cancer Society. JAMA. In press.
77. Saslow D, Boetes C, Burke W, et al., American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007; 57: 75-89.